167 related articles for article (PubMed ID: 24090564)
1. Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use.
Magné N; Chargari C; Levy A; Guy JB; Merrouche Y; Spano JP
J Chemother; 2014 Aug; 26(4):253-5. PubMed ID: 24090564
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapy of colorectal cancer: state of the art, challenges and new approaches.
Sarmiento R; Longo R; Gasparini G
Int J Biol Markers; 2012 Dec; 27(4):e286-94. PubMed ID: 23280126
[TBL] [Abstract][Full Text] [Related]
3. Current role of bevacizumab in colorectal cancer.
Saltz L
Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
[No Abstract] [Full Text] [Related]
4. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Budai B; Nagy T; Láng I; Hitre E
Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
[TBL] [Abstract][Full Text] [Related]
5. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in elderly patients with metastatic colorectal cancer.
Sclafani F; Cunningham D
J Geriatr Oncol; 2014 Jan; 5(1):78-88. PubMed ID: 24484722
[TBL] [Abstract][Full Text] [Related]
7. [Metastatic colorectal carcinoma: bevacizumab extends total survival].
Pflege Z; 2013 Apr; 66(4):252. PubMed ID: 23634556
[No Abstract] [Full Text] [Related]
8. Use of bevacizumab in the treatment of metastatic colorectal cancer.
Raouf S; Bridgewater J; Ellis R; Ferry D; Hill M; Wasan H
Br J Hosp Med (Lond); 2012 Jan; 73(1):25-30. PubMed ID: 22241406
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
10. Unusual ischemic complication of bevacizumab treatment for metastatic colorectal carcinoma.
Ryan EM; Hanly A; Morrin MM; McNamara DA
J Clin Oncol; 2013 Oct; 31(30):e433-4. PubMed ID: 23775957
[No Abstract] [Full Text] [Related]
11. Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?
Salazar R; Grasselli J; Santos C; Tabernero J
Future Oncol; 2014 Feb; 10(2):149-52. PubMed ID: 24490598
[No Abstract] [Full Text] [Related]
12. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
Saif MW
Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases.
Bhaskara A; Eng C
Clin Colorectal Cancer; 2008 Jan; 7(1):65-8. PubMed ID: 18279580
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.
Khoja L; Kumaran G; Zee YK; Murukesh N; Swindell R; Saunders MP; Clamp AR; Valle JW; Wilson G; Jayson GC; Hasan J
J Clin Gastroenterol; 2014; 48(5):430-4. PubMed ID: 24153157
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
16. The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
Terazawa T; Nishitani H; Kato K; Hashimoto H; Akiyoshi K; Iwasa S; Nakajima TE; Hamaguchi T; Yamada Y; Shimada Y
Anticancer Res; 2014 Feb; 34(2):1053-6. PubMed ID: 24511054
[TBL] [Abstract][Full Text] [Related]
17. Oral anti-angiogenesis treatment plus chemotherapy is not more efficacious than bevacizumab plus chemotherapy in metastatic colorectal cancer.
Oncology (Williston Park); 2011 Nov; 25(12):1232. PubMed ID: 22229221
[No Abstract] [Full Text] [Related]
18. Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer.
Varol U; Yildiz I; Salman T; Karabulut B; Uslu R
Tumori; 2014; 100(4):370-6. PubMed ID: 25296585
[TBL] [Abstract][Full Text] [Related]
19. Managing patients with metastatic colorectal cancer on bevacizumab.
Lemmens L; Claes V; Uzzell M
Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.
Hurwitz HI; Honeycutt W; Haley S; Favaro J
Clin Colorectal Cancer; 2006 May; 6(1):66-9. PubMed ID: 16796794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
